AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05815173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles.
Study NCT06558058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg film-coated tablet
Description: One tablet of the test drug was given orally after an overnight fast.
Study NCT06558058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto 10 mg film-coated tablet
Description: One tablet of the reference drug was given orally after an overnight fast.
Study NCT06317597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Study NCT05034081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: body contouring
Description: any post-bariatric body contouring surgery included
Study NCT05482204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Climate Impact label
Description: Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
Study NCT05482204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Climate Impact label
Description: Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
Study NCT05270122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with ThrombX Retriever
Description: Revascularization
Study NCT05604274 — intervention group
Intervention type: OTHER
Intervention: App to monitor stool consistency and symptoms
Description: App to monitor stool consistency and symptoms
Study NCT06631066 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
Study NCT06224894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy
Study NCT06224894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antiemetic treatment
Description: antiemetic treatment
Study NCT06541132 — intervention group
Intervention type: OTHER
Intervention: Observational study without human intervention
Description: Observational study without human intervention
Study NCT04184206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 1
Description: 14-day smartphone-based audio-guided attention training program with heavy mindfulness component
Study NCT04184206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 2
Description: 14-day smartphone-based audio-guided attention training program with moderate mindfulness component
Study NCT05560113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
Study NCT04184206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 3
Description: 14-day smartphone-based audio-guided attention training program without mindfulness component
Study NCT05560113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous theta burst stimulation (cTBS)
Description: This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
Study NCT05379530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG)
Description: Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
Study NCT05816200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Light Therapy
Description: Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
Study NCT05816200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
Study NCT05433259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight orthokeratology
Description: Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
Study NCT05379530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesia Provider Survey
Description: Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
Study NCT05482451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
Study NCT05482451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
Study NCT05894226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral mesh rectopexy
Description: patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
Study NCT05593133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pnf exercises
Description: PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
Study NCT05593133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training exercises
Description: gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
Study NCT06318871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Description: Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
Study NCT06318871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
Study NCT06467097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT(Stereotatic Body Radiation Therapy)
Description: Patients will receive treatment for one to two weeks, one to five times per region.
Study NCT04504903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy For Work Success (CBTw)
Description: Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.
Study NCT04504903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
Study NCT04191161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing the rigid brace
Description: Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
Study NCT04191161 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearing the rigid brace
Description: Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
Study NCT06382506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of Cornbread with Hazelnut Bread
Description: Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
Study NCT05376605 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: Evaluations of the patients will be made with scales, questionnaires and physical tests.
Study NCT05944211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator.
Study NCT06305988 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
Study NCT06305988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The anode patch is placed in Fz, and the cathode patch is placed on right cheek, powered by direct current with a current of 1.5mA. Subjects in the placebo comparator group will receive sham tDCS for 1 week, which mimics the tDCS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs. The anode patch is placed at Fz, and the cathode patch is positioned on the right cheek, to maintain the blinding of the intervention.
Study NCT06165926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% hypertonic dextrose
Description: The solution is prepared with 3 ml of 50% Dextrose, 1 ml of 2% xylocaine, and 6 ml of normal saline.~The ultrasound-guided injection of 15% hypertonic dextrose is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with hypertonic dextrose is performed at the fourth weeks. A total of 2 sessions of hypertonic dextrose injections are performed.
Study NCT06165926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The solution is prepared with 1 ml of 2% xylocaine + 9 ml of normal saline. The ultrasound-guided injection of Normal saline(0.9%) is performed at the first week. Subsequent ultrasound-guided shoulder joint injection treatment with Normal saline is performed at the fourth weeks. A total of 2 sessions of Normal saline injections are performed.
Study NCT06165926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
Study NCT06165926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy
Description: Under the guidance and supervision of a physical therapist, the patient undergoes physical therapy sessions twice a week for a total duration of 8 weeks. Each session lasts approximately 30 minutes and includes joint activities, stretching, and muscle-strengthening exercises.
Study NCT05512949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
Study NCT05512949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JYNNEOS
Description: JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
Study NCT05998590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein supplement
Description: The participants received a 60g protein bolus each evening prior to sleep from week 3 to week 12 of training.
Study NCT05998590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate protein supplement
Description: The participants received a 20g protein bolus each evening prior to sleep from week 3 to week 12 of training.
Study NCT05998590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate placebo
Description: The participants received an isocaloric carbohydrate bolus each evening prior to sleep from week 3 to week 12 of training.
Study NCT05998590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control: No supplementation
Description: The participants did not receive any supplementation but instead acted as a control group doing BT only
Study NCT05391048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(20mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
Study NCT05391048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297(10mg)
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Study NCT06085820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (birth ball)
Description: It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions.
Study NCT06085820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (birth dance)
Description: Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman.
Study NCT05822271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthognathic Surgery
Description: Type of surgery performed to correct skeletal malocclusions
Study NCT05822271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic Surgery
Description: Type of surgery performed to correct skeletal malocclusions
Study NCT04579510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novel monovalent oral poliovirus vaccine type 2 (nOPV2)
Description: nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
Study NCT04579510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent oral poliovirus vaccine (bOPV)
Description: The live types 1 \& 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 \& 3 attenuated Polio viruses (Sabin strains).
Study NCT05021484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felzartamab
Description: Intravenous infusion in regular intervals over 6 months
Study NCT05021484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion in regular intervals over 6 months
Study NCT05719831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + high dose amoxicillin（H-10d）
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
Study NCT05719831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + low dose amoxicillin（L-10d)
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d